社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
老木不朽
IP属地:未知
+关注
帖子 · 268
帖子 · 268
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
老木不朽
老木不朽
·
2021-12-29
K
Novavax Shares Jumped 3% in Morning Trading<blockquote>Novavax 股价早盘上涨 3%</blockquote>
Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.
Novavax Shares Jumped 3% in Morning Trading<blockquote>Novavax 股价早盘上涨 3%</blockquote>
看
2,794
回复
评论
点赞
3
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-28
I
Gaming stocks rose in morning trading<blockquote>游戏股早盘上涨</blockquote>
Gaming stocks rose in morning trading.Roblox,Unity Software and AppLovin climbed between 1% and 3%.
Gaming stocks rose in morning trading<blockquote>游戏股早盘上涨</blockquote>
看
5,079
回复
评论
点赞
4
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-27
K
A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State<blockquote>宣布大型合作伙伴关系一年后,Ocugen 陷入了困境</blockquote>
In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, t
A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State<blockquote>宣布大型合作伙伴关系一年后,Ocugen 陷入了困境</blockquote>
看
2,806
回复
1
点赞
5
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-26
K
非常抱歉,此主贴已删除
看
3,634
回复
评论
点赞
3
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-25
K
非常抱歉,此主贴已删除
看
4,563
回复
1
点赞
2
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-24
O
Tencent ADR rose more than 4% in early trading<blockquote>腾讯控股ADR早盘上涨逾4%</blockquote>
Tencent ADR rose more than 4% in early trading.Tencent said on Thursday it will transfer HK$127.69 b
Tencent ADR rose more than 4% in early trading<blockquote>腾讯控股ADR早盘上涨逾4%</blockquote>
看
3,134
回复
1
点赞
5
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-23
K
非常抱歉,此主贴已删除
看
2,944
回复
评论
点赞
6
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-22
K
非常抱歉,此主贴已删除
看
3,015
回复
评论
点赞
3
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-21
K
非常抱歉,此主贴已删除
看
3,535
回复
1
点赞
5
编组 21备份 2
分享
举报
老木不朽
老木不朽
·
2021-12-20
K
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>
The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>
看
4,619
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3548659340886358","uuid":"3548659340886358","gmtCreate":1585565882360,"gmtModify":1619863267814,"name":"老木不朽","pinyin":"lmbxlaomubuxiu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":32,"headSize":644,"tweetSize":268,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.66%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":696596739,"gmtCreate":1640729711513,"gmtModify":1640729711849,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696596739","repostId":"1150918555","repostType":4,"repost":{"id":"1150918555","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640702663,"share":"https://www.laohunote.com/m/news/1150918555?lang=zh_CN&edition=full","pubTime":"2021-12-28 22:44","market":"us","language":"en","title":"Novavax Shares Jumped 3% in Morning Trading<blockquote>Novavax 股价早盘上涨 3%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1150918555","media":"Tiger Newspress","summary":"Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.","content":"<p>Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.</p><p><blockquote>Novavax 股价在早盘交易中上涨 3%。该股昨天暴跌近11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d7f50d71385e7262972c51f222a641a6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Shares Jumped 3% in Morning Trading<blockquote>Novavax 股价早盘上涨 3%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Shares Jumped 3% in Morning Trading<blockquote>Novavax 股价早盘上涨 3%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-28 22:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.</p><p><blockquote>Novavax 股价在早盘交易中上涨 3%。该股昨天暴跌近11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d7f50d71385e7262972c51f222a641a6\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150918555","content_text":"Novavax shares jumped 3% in morning trading.The stock plunged nearly 11% yesterday.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696370960,"gmtCreate":1640639824259,"gmtModify":1640639824614,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"I","listText":"I","text":"I","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696370960","repostId":"1102433799","repostType":4,"repost":{"id":"1102433799","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640617949,"share":"https://www.laohunote.com/m/news/1102433799?lang=zh_CN&edition=full","pubTime":"2021-12-27 23:12","market":"us","language":"en","title":"Gaming stocks rose in morning trading<blockquote>游戏股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102433799","media":"Tiger Newspress","summary":"Gaming stocks rose in morning trading.Roblox,Unity Software and AppLovin climbed between 1% and 3%.","content":"<p>Gaming stocks rose in morning trading.Roblox,Unity Software and AppLovin climbed between 1% and 3%.</p><p><blockquote>游戏股早盘上涨.Roblox、Unity Software 和 AppLovin 上涨 1% 至 3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/580cc77260d26ccb370ef7f324be78b5\" tg-width=\"419\" tg-height=\"419\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gaming stocks rose in morning trading<blockquote>游戏股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGaming stocks rose in morning trading<blockquote>游戏股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-27 23:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Gaming stocks rose in morning trading.Roblox,Unity Software and AppLovin climbed between 1% and 3%.</p><p><blockquote>游戏股早盘上涨.Roblox、Unity Software 和 AppLovin 上涨 1% 至 3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/580cc77260d26ccb370ef7f324be78b5\" tg-width=\"419\" tg-height=\"419\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102433799","content_text":"Gaming stocks rose in morning trading.Roblox,Unity Software and AppLovin climbed between 1% and 3%.","news_type":1,"symbols_score_info":{"RBLX":0.9}},"isVote":1,"tweetType":1,"viewCount":5079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698714702,"gmtCreate":1640552770112,"gmtModify":1640552770531,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698714702","repostId":"1144001147","repostType":4,"repost":{"id":"1144001147","kind":"news","pubTimestamp":1640485026,"share":"https://www.laohunote.com/m/news/1144001147?lang=zh_CN&edition=full","pubTime":"2021-12-26 10:17","market":"us","language":"en","title":"A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State<blockquote>宣布大型合作伙伴关系一年后,Ocugen 陷入了困境</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144001147","media":"InvestorPlace","summary":"In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, t","content":"<p><div> In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there...</p><p><blockquote><div>去年,Ocugen(纳斯达克股票代码:OCGN)股票仍然是表现最好的股票之一。在此期间,该股飙升超过500%。该股的上涨始于 2020 年 12 月 21 日之后--从那里开始...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State<blockquote>宣布大型合作伙伴关系一年后,Ocugen 陷入了困境</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Year After Announcing a Big Partnership, Ocugen Is in a Sorry State<blockquote>宣布大型合作伙伴关系一年后,Ocugen 陷入了困境</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-26 10:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there...</p><p><blockquote><div>去年,Ocugen(纳斯达克股票代码:OCGN)股票仍然是表现最好的股票之一。在此期间,该股飙升超过500%。该股的上涨始于 2020 年 12 月 21 日之后--从那里开始...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144001147","content_text":"In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there, the stock is up over 1,600%.\nHowever, it’s worth noting that OCGN stock was trading well below one dollar before it stitched a partnership with Bharat Biotech. The companies announced plans to begin manufacturing Covid-19 vaccines in the U.S. on Dec. 22 last year.\nBeyond the news of this partnership, there has been little to cheer for investors. OCGN stock traded at all-time highs of $18.77 in February and reached slightly lower peaks in May and November. The stock traded at $5.12 at the start of Dec. 23.\nOcugen will continue to underperform going forward. Even after the downtrend in the last few months, OCGN stock should be avoided.\nLet’s talk about the reasons to be bearish.\nFDA Approval Remains Elusive\nPfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA) have been leaders in the vaccine race in the U.S. In a country where more than 70% of the population has already been vaccinated, Ocugen has yet to secure an approval from the U.S. Food and Drug Administration.\nBack in June, the biotech company’s application for emergency use authorization was rejected by the FDA. The recommendation by the FDA was to file for a biologics license application, which implies full approval.\nIn November, Ocugen announced that the FDA has “issued a clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate.” The FDA will be identifying the specific deficiencies that form a basis for the clinical hold. Once Ocugen addresses these deficiencies, there will be some progress.\nThe key point is that it’s been over a year since Ocugen announced the partnership with Bharat Biotech. The company has still been unsuccessful from an approval perspective.\nIn July, Ocugen had also initiated a rolling submission to Health Canada for the vaccine. There is no positive news on that front either.\nLet’s imagine a scenario where Ocugen receives an approval for vaccine use in Q1 2022. This is very unlikely. However, even in an optimistic case scenario, Ocugen needs to compete in a market where vaccination percentage is high. There is unlikely to be a case for strong revenue and cash flow growth.\nCan Omicron Provide a Lifeline for OCGN Stock?\nThe omicron variant has been a cause of concern for governments globally. Ocugen and partner Bharat Biotech are currently studying the effectiveness of the vaccine against the variant.\nIf the vaccine proves to be effective, can it be a game-changer for Ocugen? Most likely, no.\nFirst and foremost, Moderna has announced that its Covid-19 booster increases neutralizing antibodies 37-fold against Omicron variant.\nFurthermore, Pfizer has announced that a third dose increases the “neutralizing antibody by 25-fold compared to two doses against the Omicron variant.”\nClearly, the leading vaccine makers have an edge. Even if Ocugen announces that its vaccine is effective against the omicron variant, the stock is unlikely to trend higher.\nPeople who have already taken two shots of Moderna or Pfizer are unlikely to pursue a booster shot with Ocugen. Additionally, Ocugen is still struggling for approval.\nIt’s also worth noting that Ocugen needs to share revenue with Bharat Biotech. The visibility for healthy cash flows is therefore very unlikely.\nOCGN Stock Will Trend Lower\nOCGN stock is likely to continue trending lower in the coming months. Without an approval, the company is rapidly losing out on any revenue and cash flow potential.\nThe company is building a pipeline of drugs for various indications. However, the pipeline for various indications is still at a pre-clinical stage.\nThe stock trend will therefore be dictated by the outcome of Covid-19 vaccine approval and revenue potential. Things seem bleak on that front.\nIt also seems unlikely that Ocugen has a capability to expand the vaccine partnership with Bharat Biotech to other countries.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698562609,"gmtCreate":1640468920805,"gmtModify":1640469213054,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698562609","repostId":"2193720178","repostType":4,"isVote":1,"tweetType":1,"viewCount":3634,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698681202,"gmtCreate":1640379716041,"gmtModify":1640379716545,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698681202","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":4563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698946150,"gmtCreate":1640294903136,"gmtModify":1640295366828,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698946150","repostId":"1177863167","repostType":4,"repost":{"id":"1177863167","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640270946,"share":"https://www.laohunote.com/m/news/1177863167?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:49","market":"us","language":"en","title":"Tencent ADR rose more than 4% in early trading<blockquote>腾讯控股ADR早盘上涨逾4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177863167","media":"Tiger Newspress","summary":"Tencent ADR rose more than 4% in early trading.Tencent said on Thursday it will transfer HK$127.69 b","content":"<p>Tencent ADR rose more than 4% in early trading.<img src=\"https://static.tigerbbs.com/5c64eef1168fcdac16b6cdfe487310c5\" tg-width=\"707\" tg-height=\"595\" width=\"100%\" height=\"auto\">Tencent said on Thursday it will transfer HK$127.69 billion ($16.37 billion) worth of its JD.com stake to shareholders, slashing its holding in China's second-biggest e-commerce company to 2.3% from around 17% now and losing its spot as JD.com's biggest shareholder to Walmart(WMT.N).</p><p><blockquote>腾讯控股ADR早盘上涨逾4%。腾讯控股周四表示,将把价值 1276.9 亿港元(163.7 亿美元)的京东股份转让给股东,将其在中国第二大电子商务公司的持股比例从目前的约 17% 削减至 2.3%,并失去京东最大股东的地位沃尔玛 (WMT.N)。</blockquote></p><p> The owner of WeChat, which first invested in JD.com in 2014, said it was the right time for the divestment, given the e-commerce firm had reached a stage where it can self-finance its growth.</p><p><blockquote>2014年首次投资京东的微信老板表示,鉴于这家电子商务公司已经到了可以自筹资金实现增长的阶段,现在是撤资的合适时机。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent ADR rose more than 4% in early trading<blockquote>腾讯控股ADR早盘上涨逾4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent ADR rose more than 4% in early trading<blockquote>腾讯控股ADR早盘上涨逾4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-23 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tencent ADR rose more than 4% in early trading.<img src=\"https://static.tigerbbs.com/5c64eef1168fcdac16b6cdfe487310c5\" tg-width=\"707\" tg-height=\"595\" width=\"100%\" height=\"auto\">Tencent said on Thursday it will transfer HK$127.69 billion ($16.37 billion) worth of its JD.com stake to shareholders, slashing its holding in China's second-biggest e-commerce company to 2.3% from around 17% now and losing its spot as JD.com's biggest shareholder to Walmart(WMT.N).</p><p><blockquote>腾讯控股ADR早盘上涨逾4%。腾讯控股周四表示,将把价值 1276.9 亿港元(163.7 亿美元)的京东股份转让给股东,将其在中国第二大电子商务公司的持股比例从目前的约 17% 削减至 2.3%,并失去京东最大股东的地位沃尔玛 (WMT.N)。</blockquote></p><p> The owner of WeChat, which first invested in JD.com in 2014, said it was the right time for the divestment, given the e-commerce firm had reached a stage where it can self-finance its growth.</p><p><blockquote>2014年首次投资京东的微信老板表示,鉴于这家电子商务公司已经到了可以自筹资金实现增长的阶段,现在是撤资的合适时机。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","TCEHY":"腾讯控股ADR"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177863167","content_text":"Tencent ADR rose more than 4% in early trading.Tencent said on Thursday it will transfer HK$127.69 billion ($16.37 billion) worth of its JD.com stake to shareholders, slashing its holding in China's second-biggest e-commerce company to 2.3% from around 17% now and losing its spot as JD.com's biggest shareholder to Walmart(WMT.N).\nThe owner of WeChat, which first invested in JD.com in 2014, said it was the right time for the divestment, given the e-commerce firm had reached a stage where it can self-finance its growth.","news_type":1,"symbols_score_info":{"00700":0.9,"TCEHY":0.9}},"isVote":1,"tweetType":1,"viewCount":3134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691242324,"gmtCreate":1640215883037,"gmtModify":1640215883427,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691242324","repostId":"2193113147","repostType":4,"isVote":1,"tweetType":1,"viewCount":2944,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691934747,"gmtCreate":1640120790467,"gmtModify":1640120790892,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691934747","repostId":"2193154031","repostType":4,"isVote":1,"tweetType":1,"viewCount":3015,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693235442,"gmtCreate":1640037735676,"gmtModify":1640037736009,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693235442","repostId":"2192004187","repostType":4,"isVote":1,"tweetType":1,"viewCount":3535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693052891,"gmtCreate":1639951013917,"gmtModify":1639951060264,"author":{"id":"3548659340886358","authorId":"3548659340886358","name":"老木不朽","avatar":"https://static.tigerbbs.com/5b7c249f8702df4b6d4a8a6346ce6b5d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548659340886358","authorIdStr":"3548659340886358"},"themes":[],"title":"","htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693052891","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohunote.com/m/news/1122414343?lang=zh_CN&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为 2.5%,这主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与 COVID-19 卷土重来作斗争的股票领涨,而整体指数下跌约 1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过 2B 美元且日均交易量超过 10 万股的股票中,<a href=\"https://laohu8.com/S/ARNA\">竞技场制药</a>之后上涨约 83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约 6.7B 美元的价格收购该公司,生物技术公司溢价 100%。<a href=\"https://laohu8.com/S/CERN\">塞纳</a>该公司也加入了并购驱动的涨势,本周上涨了约 20.7%,有报道称可能出价约 $30B<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商,<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>由于投资者对该公司的 COVID-19 疫苗获得世卫组织批准表示欢迎,股价上涨了约 30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会获得进一步收益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">生物港制药</a>在该公司宣布在以色列批准 NURTEC ODT (rimegepant) 后,每周上涨约 25.2%,使其成为该偏头痛药物在美国以外的首次监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约 23.7%,跻身本月第二周涨幅最大的股票之列。本周有更多数据证实了该公司与葛兰素史克公司(纽约证券交易所股票代码:GSK)合作开发的 COVID-19 疗法具有中和奥密克戎的效果。四舍五入,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了~22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>显著涨幅:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE) 本周成为头条新闻,再次上调了 COVID-19 疫苗的销售指导,因为快速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五为期六天的涨势突然结束,<a href=\"https://laohu8.com/S/NWY\">纽约</a>这家总部位于 - 的制药巨头股价上涨约 12.7%,创下自 2009 年 3 月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新上市的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街的评级很好,但分别下跌了19.3%和约13.5%。与此同时,处方药价格比较平台运营商 GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约 15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周最佳表演者、<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一发布的卖出评级的影响<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本上积极的看法开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)股价下跌约 12.3%,此前该公司在 ASH 上介绍了实验性 allogeneic 的 1 期数据。<a href=\"https://laohu8.com/S/00699\">车</a>T therapies 未能让投资者兴奋不已,其中包括凯西-伍德(Cathie Wood)的方舟投资管理公司(Ark Investment Management),该公司在几天后卖出了约 160 万股该生物技术公司的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir 跻身医疗保健涨幅之列,辉瑞创下十年来最佳涨势</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-19 11:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为 2.5%,这主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与 COVID-19 卷土重来作斗争的股票领涨,而整体指数下跌约 1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过 2B 美元且日均交易量超过 10 万股的股票中,<a href=\"https://laohu8.com/S/ARNA\">竞技场制药</a>之后上涨约 83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约 6.7B 美元的价格收购该公司,生物技术公司溢价 100%。<a href=\"https://laohu8.com/S/CERN\">塞纳</a>该公司也加入了并购驱动的涨势,本周上涨了约 20.7%,有报道称可能出价约 $30B<a href=\"https://laohu8.com/S/ORCL\">甲骨文</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商,<a href=\"https://laohu8.com/S/NVAX\">诺瓦瓦克斯</a>由于投资者对该公司的 COVID-19 疫苗获得世卫组织批准表示欢迎,股价上涨了约 30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会获得进一步收益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">生物港制药</a>在该公司宣布在以色列批准 NURTEC ODT (rimegepant) 后,每周上涨约 25.2%,使其成为该偏头痛药物在美国以外的首次监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约 23.7%,跻身本月第二周涨幅最大的股票之列。本周有更多数据证实了该公司与葛兰素史克公司(纽约证券交易所股票代码:GSK)合作开发的 COVID-19 疗法具有中和奥密克戎的效果。四舍五入,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了~22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>显著涨幅:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE) 本周成为头条新闻,再次上调了 COVID-19 疫苗的销售指导,因为快速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五为期六天的涨势突然结束,<a href=\"https://laohu8.com/S/NWY\">纽约</a>这家总部位于 - 的制药巨头股价上涨约 12.7%,创下自 2009 年 3 月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新上市的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街的评级很好,但分别下跌了19.3%和约13.5%。与此同时,处方药价格比较平台运营商 GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约 15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周最佳表演者、<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一发布的卖出评级的影响<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本上积极的看法开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)股价下跌约 12.3%,此前该公司在 ASH 上介绍了实验性 allogeneic 的 1 期数据。<a href=\"https://laohu8.com/S/00699\">车</a>T therapies 未能让投资者兴奋不已,其中包括凯西-伍德(Cathie Wood)的方舟投资管理公司(Ark Investment Management),该公司在几天后卖出了约 160 万股该生物技术公司的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4007":"制药","ARNA":"阿里那","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","ORCL":"甲骨文","BK4534":"瑞士信贷持仓"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals dominated with a ~83.8% rise after Pfizer agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle for the electronic-medical-records company.\nVaccine developer, Novavax jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"PFE":0.9,"CERN":0.9,"ORCL":0.9,"ARNA":0.9}},"isVote":1,"tweetType":1,"viewCount":4619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}